Tulisokibart (MK-7240) is an investigational humanized anti-TL1A monoclonal antibody in development for immune-mediated inflammatory diseases. Merck reports ongoing Phase 3 programs in ulcerative colitis and Crohn's disease, with additional Phase 2b trials in hidradenitis suppurativa, radiographic axial spondyloarthritis, and rheumatoid arthritis. It has no marketing approval.
Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07486960 |
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) |
RECRUITING | PHASE2 |
| NCT07176390 |
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) |
RECRUITING | PHASE2 |
| NCT07133633 |
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) |
RECRUITING | PHASE2 |
| NCT06956235 |
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06829225 |
Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) |
COMPLETED | PHASE1 |
| NCT06651281 |
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) |
RECRUITING | PHASE3 |
| NCT06575595 |
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) |
COMPLETED | PHASE1 |
| NCT05270668 |
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05013905 |
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006) |
COMPLETED | PHASE2 |
| NCT04996797 |
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) |
COMPLETED | PHASE2 |
